Welcure Drugs Reports FY26 Financials with Significant Auditor Disclosures
Welcure Drugs & Pharmaceuticals Ltd · Others (Uncategorized) · 02 Nov 2026, 11:15 pm
Welcure Drugs Reports FY26 Financials with Significant Auditor Disclosures Welcure Drugs & Pharmaceuticals approved corrected standalone results for the year ended 31st Mar'26, superseding its 29th May'26 filing. FY26 revenue surged to ₹38,952.44 lakh versus ₹2,455.00 lakh in FY25, driven entirely by the agriculture segment. However, the company posted a net loss of ₹567.08 lakh compared to a profit of ₹217.01 lakh in FY25. Statutory auditors issued an unmodified opinion with substantial emphasis of matters, noting unconfirmed supplier advances of ₹15,126.13 lakh, unverifiable sales invoices lacking e-way bills, and unverified inventory of ₹143,52.36 lakh.
Original exchange filing (PDF)
More announcements from Welcure Drugs & Pharmaceuticals Ltd
- Outcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Ltd held on today i.e. Tuesday, 14th July, 2026. · 14 Jul 2026
- Resignation of Company Secretary and Compliance Officer · 19 Jun 2026
- Outcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on Today i.e. Friday, 19th June, 2026 · 19 Jun 2026
- Audited Standalone Financial Results for the Quarter and Year Ended 31st March, 2026 · 30 May 2026
- Outcome of the Meeting of Board of Directors of the Company held on today i.e. Friday, 29th May, 2026 · 30 May 2026
- Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Audited Financial .... · 29 May 2026
- <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> .... · 23 Apr 2026
- Unaudited Financials Results for the 3rd Quarter ended on 31st December, 2025 · 13 Feb 2026
